Bilal Arshad Khan - 09 Feb 2026 Form 4 Insider Report for SpyGlass Pharma, Inc. (SGP)

Reporting relationship: Director
Issuer ticker: SGP
Reported as of: 09 Feb 2026
Net transaction value: +$2,160,000
SEC form: 4
Accepted by SEC: 11 Feb 2026, 16:07:19 UTC
Prior SEC filing: 05 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Brian Aukshunas, as Attorney-in-Fact

Key filing fact

Bilal Arshad Khan filed Form 4 for SpyGlass Pharma, Inc. (SGP) on 11 Feb 2026.

Key facts

This page summarizes Bilal Arshad Khan's Form 4 filing for SpyGlass Pharma, Inc. (SGP).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 11 Feb 2026, 16:07.

Change

Previous filing in this sequence was filed on 05 Feb 2026.
Current net transaction value: +$2,160,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002108044 Primary reporting owner

Khan Bilal Arshad

Relationship: Director
Address: C/O SPYGLASS PHARMA, INC., 27061 ALISO CREEK RD., SUITE 100, ALISO VIEJO
Signature: /s/ Brian Aukshunas, as Attorney-in-Fact
Signature date: 11 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SGP transaction

Common Stock

Purchase

Transaction value: $320,000
Shares: +20,000
Change %: +367%
Price: $16.00
Shares after: 25,450
Date: 09 Feb 2026
Ownership: Direct

SGP transaction

Common Stock

Purchase

Transaction value: $1,840,000
Shares: +115,000
Change %: +84%
Price: $16.00
Shares after: 251,427
Date: 09 Feb 2026
Ownership: See footnote
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares held by New World Medical, Inc. (New World Medical). The Reporting Person is the Chief Executive Officer of New World Medical and as such has voting and investment control over the shares held by New World Medical. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of their pecuniary interest in the shares.